Exelixis
EXEL
#1855
Rank
NZ$18.81 B
Marketcap
NZ$70.19
Share price
2.33%
Change (1 day)
3.78%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): NZ$4.01

According to Exelixis's latest financial reports the company's current EPS (TTM) is NZ$4.01. In 2023 the company made an earnings per share (EPS) of NZ$1.10 an increase over its 2022 EPS that were of NZ$0.96.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$4.01
2023NZ$1.1014.61%
2022NZ$0.96-22.97%
2021NZ$1.25100%
2020NZ$0.62-65.09%
2019NZ$1.78-53.91%
2018NZ$3.87333.96%
2017NZ$0.89-260.61%
2016NZ-$0.56-58.75%
2015NZ-$1.35-42.45%
2014NZ-$2.345.3%
2013NZ-$2.22

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
NZ$18.75 367.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$2.29-42.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$24.12 502.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$3.48-13.23%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$12.30 207.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$5.00 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
NZ$6.34 58.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
NZ-$6.18-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
NZ-$1.41-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA